Explore Our Pipeline
Read the Science
Clinical-Stage Bioenergetics

Controlled mitochondrial uncoupling therapies

Rivus Pharmaceuticals is advancing HU6, a first-in-class oral small molecule designed to address cellular energy regulation directly, preserving lean mass while reducing systemic fat.

A close-up shot of a clinical scientist in a sterile laboratory environment, analyzing metabolic data on a high-resolution screen, cool blue and white ambient lighting, professional depth of field
A close-up shot of a clinical scientist in a sterile laboratory environment, analyzing metabolic data on a high-resolution screen, cool blue and white ambient lighting, professional depth of field
Phase 2a Data

Preserving lean muscle mass

Our lead candidate, HU6, targets the root cause of metabolic dysfunction by safely accelerating cellular energy consumption. Phase 2a clinical data demonstrates significant reduction in liver fat while preserving critical lean muscle mass.

33%

Reduction in liver fat

Zero

Significant lean muscle loss

Therapeutic Pipeline

Advancing oral small molecules

Our pipeline of disease-modifying oral therapies targets mitochondrial biology to address the spectrum of MASH, obesity, and related cardiometabolic dysfunctions, offering highly credible alternatives to injectable treatments.

Lead Candidate
Investigational Therapy

HU6: Mitochondrial Uncoupler

RV-8451: Oral GLP-1

Currently in Phase 2 development for MASH and obesity. Designed to safely increase energy expenditure and reduce systemic fat while protecting vital lean tissue.

A novel oral GLP-1 receptor agonist designed for metabolic regulation, expanding our cellular bioenergetics platform into broader cardiometabolic indications.

Strategic Partnerships

Collaborate on cellular bioenergetics

We actively collaborate with institutional investors, clinical investigators, and strategic pharmaceutical partners to accelerate the development of our cellular bioenergetics platform.